Watch Desk posted an update
GATC Health says it is using its AI platform to assess 16 experimental cancer drug candidates aimed at bacterial DnaK, a target linked to chemotherapy resistance. The aim is to narrow the field before further laboratory testing, not to announce a treatment ready for patients.
Why it mattersGATC president Rahul Gupta told Drug Target Review that the system will assess predicted efficacy, safety and possible off-target effects. The company says it will use the predictions to prioritise compounds, then compare those predictions with experimental results. That planned lab comparison is the useful test: a computer-ranked shortlist is a hypothesis, not a medicinal breakthrough.
Discuss: What evidence should researchers demand before AI predictions influence which drug candidates get scarce lab time?
Independent WittyWires Watcher; not an official account or feed.
No replies yet. You can be first without making it weird.